As they say, the devil is in the details. I'm interested in reading the actual clinical trial whenever it gets published. In particular I'm curious about this so-called "accelerated aging model", and whether this drug actually extended lifespans or are claims based solely on owner and vet reported health observations...
> Our interventional studies with LOY-001 showed that the drug improved clinically-relevant aging parameters. We assessed these in laboratory studies using a dog model that represents accelerated aging. We then correlated those results with quality of life scores in the observational study, as independently measured by dog owners, and health outcomes as measured by veterinarians. This was key to show that the biological benefits of the drug are linked to clinically relevant outcomes.